Neumonía por Pneumocystis jirovecii posterior a COVID-19 en un paciente sin infección por VIH / Pneumonia by Pneumocystis jirovecii after COVID-19 in non-HIV patient

Resumen La neumonía oportunista por Pneumocystis jirovecii en pacientes con una infección respiratoria grave por SARS-CoV-2 es una entidad recién reconocida, asociada a la terapia con corticoesteroides junto a otros factores de riesgo predisponentes. Supone un reto diagnóstico y, tras el tratamiento, el pronóstico es favorable. Presentamos el caso de un varón con neumonía grave por SARS-CoV-2 que recibió tratamiento corticoidal, desarrollando posteriormente una neumonía por P. jirovecii.

Abstract Infection by Pneumocystis jirovecii in patients with severe respiratory infection caused by SARS-CoV-2 is a situation that we must take into account today. Corticotherapy along with other risk factors predisposes to it. It is a diagnostic challenge and, after treatment, the prognosis is favorable. We report the case of a male with severe pneumonia due to SARS-CoV-2 who received corticosteroid treatment, later developing pneumonia due to P. jiroveci.

Pneumocystis jirovecii Pneumonia in Patients with Lung Cancer: A Review / 中国肺癌杂志

In recent years, with the widespread use of immunodepressant agents, Pneumocystis jirovecii pneumonia (PJP) has been significantly found in non-human immunodeficiency virus (HIV) patients, such as those with malignancies, post-transplantation and autoimmune diseases. Although the risk factors and management of PJP have been extensively studied in the hematologic tumor and post-transplant populations, the research on real tumor cases is insufficient. Lung cancer has been the most common tumor with the highest number of incidence and death worldwide, and the prognosis of lung cancer patients infected with PJP is poor in clinical practice. By reviewing the previous studies, this paper summarized the epidemiology and clinical manifestations of PJP in lung cancer patients, the risk factors and possible mechanisms of PJP infection in lung cancer patients, diagnosis and prevention, and other research progresses to provide reference for clinical application.
.

Diagnóstico simultáneo y evolución favorable de infección por Pneumocystis jirovecii, SARS-CoV-2 Y HIV avanzada / Simultaneous diagnosis and favorable evolution of infection with Pneumocystis jirovecii, SARS-CoV-2 and advanced HIV

Resumen El SARS-CoV-2 es el virus causante de la enfermedad COVID-19, desconocida antes del brote que ocurrió en diciembre de 2019 en Wuhan, China, y desencadenó la actual pandemia. Las manifestaciones de la infección por SARS-CoV-2 son muy variables entre los pacientes. Los peores desenlaces se suelen asociar a edad avanzada y factores de riesgo reconocidos. Entre estos sería razonable considerar los distintos tipos de inmunodeficiencia, en particular la producida por HIV. Sin embargo, no existen hasta el momento, estudios que demuestren que la infección HIV empeore la evolución y el pronóstico de COVID-19. La neumonía por el hongo Pneumocystis jirovecii (antes denominado P. carinii) afecta con mayor frecuencia a inmunodeprimidos y puede tener desenlace fatal. Exponemos el caso de una mujer de mediana edad con síndrome de Raynaud que ingresó con neumonía y durante la internación se le diagnosticó infección simultánea por HIV, SARS-CoV-2 y P. jirovecci. Evolucionó de forma favorable con tratamiento empírico sin requerir maniobras invasivas ni soporte ventilatorio, logrando el alta y seguimiento de forma ambulatoria.

Abstract SARS-CoV-2 causes the disease named COVID-19, which emerged in Wuhan, China, in December 2019 and developed into the current pandemic. The manifestations of SARS-CoV-2 infection are highly variable. The worst outcomes are usually associated with advanced age and known risk factors. Among these, it would be reasonable to consider conditions compromising the immune system, particularly the immunodeficiency associated to HIV. To date, however, there is no evidence of HIV infection worsening the evolution and prognosis of COVID-19. Pneumocystis jirovecii (previously-P. carinii) pneumonia, is a fungal disease that most commonly affects immunocompromised persons and can be life-threatening. Typically, patients at risk are those with any underlying condition altering host immunity. We present the case of a middle-aged woman with Raynaud's syndrome who was admitted with pneumonia. During hospitalization she was simultaneously diagnosed with infection by HIV, COVID-19 and P. jirovecci. The patient evolved favorably upon empirical treatment without requiring invasive maneuvers or ventilatory support. Outpatient follow-up after hospital discharge was uneventful.

Detección y genotipificación de Pneumocystis jirovecii en muestras de pacientes mexicanos VIH positivos y negativos / Detection and genotyping of Pneumocystis jirovecii in samples from HIV positive and negative Mexican patients

Resumen Introducción: Pneumocystis jirovecii es un hongo atípico detectado particularmente en pacientes VIH-positivos o con trasplante. Objetivo: Detectar y genotipificar Pneumocystis jirovecii en muestras de pacientes de dos hospitales de la ciudad de México. Método: Fueron procesadas 89 muestras respiratorias, correspondientes a 53 pacientes (30 VIH positivos y 23 VIH negativos) con sintomatología respiratoria y 11 personas sanas incluidas como control negativo. El DNA fue extraído y amplificado por PCR anidada de la región del espaciador transcrito interno, obteniendo un fragmento en cada ronda (de 693 y 550 pb). Los genotipos y su relación filogenética fueron determinados por secuenciación del fragmento de 550 pb. Resultados: Cuarenta y ocho muestras de 30 pacientes VIH-positivos provenían de un solo hospital, de las cuales 11 (36.6 %) fueron positivas a Pneumocystis jirovecii. Ninguna fue positiva en pacientes VIH-negativos o personas sanas. Los haplotipos detectados con mayor frecuencia fueron Eg y Em. Conclusiones: La frecuencia de infección por Pneumocystis jirovecii fue alta en la población mexicana estudiada. El genotipo más frecuente fue diferente a los reportados en otros países. Es necesario encauzar este problema de salud hacia la detección temprana de esta infección.

Abstract Introduction: Pneumocystis jirovecii is an atypical fungus particularly detected in HIV-positive or transplant patients. Objective: To detect and genotype Pneumocystis jirovecii in patient samples from two hospitals in Mexico City. Method: Eighty-nine respiratory tract samples, corresponding to 53 patients (30 HIV-positive and 23 HIV-negative) with respiratory symptoms and to 11 healthy individuals included as negative control, were processed. DNA was extracted from the ITS region and amplified by nested polymerase chain reaction from the internal transcribed spacer, with one fragment being obtained at each round (693 and 550 bp). Genotypes and their phylogenetic relationship were determined by sequencing the 550 bp fragment. Results: Forty-eight samples from 30 HIV-positive patients were received from a single hospital, out of which 11 (36.6 %) were positive for Pneumocystis jirovecii. No sample was positive in HIV-negative patients or healthy subjects. The most frequently detected haplotypes were Eg and Em. Conclusions: The frequency of Pneumocystis jirovecii infection was high in the studied Mexican population. The most common genotype was different from those reported in other countries. It is necessary to address this health problem through early detection of this infection.

Neumonia por Pneumocystis jirovecii en niño inmunocompetente: revisión de un caso / Pneumocystis jirovecii in immunocompetent children: a case report

We describe an unusual case of severe pneumonia due to Pneumocystis jirovecii in a previously healthy 2-month-old patient who had been hospitalized for RSV bronchiolitis.

Se describe un caso inusual de neumonía grave por Pneumocystis jirovecci en un paciente de 2 meses de vida previamente sano, quien había sido hospitalizado por una bronquiolitis por VRS.

Optimización y validación de un método de PCR en tiempo real para el diagnóstico de Pneumocystis jirovecii en muestras respiratorias de pacientes pediátricos / Optimization and validation of a real-time PCR method for the diagnosis of Pneumocystis jirovecii in respiratory samples of pediatric patients

Pneumocystis jirovecii (PCP) es un hongo oportunista, que causa neumonía en pacientes con un sistema inmunitario seriamente comprometido. La prevalencia de la enfermedad disminuyó dramáticamente con la introducción de la terapia antirretroviral combinada (HAART) y actualmente las infecciones ocurren en aquellos pacientes que no reciben adecuada profilaxis o no la completan. Es una enfermedad grave con elevada tasa de mortalidad (30-60%) en pacientes oncohematológicos y receptores de trasplante de células progenitoras hematopoyéticas (HSCT), pero prevenible con profilaxis adecuada, por lo que el reconocimiento temprano de los pacientes en riesgo es crítico. El diagnóstico de certeza es de laboratorio ya que los hallazgos clínicos son inespecíficos y las imágenes no son patognomónicas de este agente. Actualmente las técnicas moleculares como la PCR en tiempo real son las metodologías recomendadas ya que poseen elevada sensibilidad, especificidad, rapidez y eficiencia. En el presente estudio se optimizó un método de PCR en tiempo real con iniciadores dirigidos al gen del ARNr de la subunidad grande mitocondrial, en formato dúplex junto con el gen constitutivo RNAsa P. El método demostró ser muy sensible y rápido para el diagnóstico clínico de PCP, con una concordancia қ: 0,789 con el método convencional de PCR anidada que emplea como target a la región espaciadora transcrita interna (ITS) del gen del ARNr de PCP, a la vez de ser mucho menos laborioso y con menor riesgo de contaminación, lo que permite el manejo de un alto número de muestras clínicas (AU)

Pneumocystis jirovecii (PCP) is an opportunistic fungus causing pneumonia in severely immunocompromised patients. Prevalence of the disease has dramatically decreased after the introduction of combined antiretroviral therapy (HAART) and currently these infections occur in patients who do not receive adequate prophylaxis or do not complete treatment. PCP is a severe disease with a high mortality rate (30-60%) in oncology-hematology patients and hematopoietic stem-cell transplantation (HSCT) recipients, but is preventable with adequate prophylaxis. Therefore, early recognition of at-risk patients is essential. Laboratory studies are the gold standard for the diagnosis as clinical findings are unspecific and imaging studies are not pathognomonic for this agent. Currently, molecular techniques, such as real-time PCR, are the methodology of choice because of their high sensitivity, specificity, speed, and efficiency. In this study, a real-time PCR method was optimized with primers targeting the gene of the mitochondrial large subunit rRNA in a duplex format together with the constitutive gene RNAsa P. The method showed to be very sensitive and fast for the clinical diagnosis of PCP, with a concordance of қ: 0.789 with the conventional nested PCR method targeting the internal transcribed spacer (ITS) region of the rRNA gene of PCP, and is much easier to perform with a lower contamination risk allowing a high through-put of clinical samples (AU)

Single Nodular Opacity of Granulomatous Pneumocystis Jirovecii Pneumonia in an Asymptomatic Lymphoma Patient

The radiologic findings of a single nodule from Pneumocystis jirovecii pneumonia (PJP) have been rarely reported. We described a case of granulomatous PJP manifesting as a solitary pulmonary nodule with a halo sign in a 69-year-old woman with diffuse large B cell lymphoma during chemotherapy. The radiologic appearance of the patient suggested an infectious lesion such as angioinvasive pulmonary aspergillosis or lymphoma involvement of the lung; however, clinical manifestations were not compatible with the diseases. The nodule was confirmed as granulomatous PJP by video-assisted thoracoscopic surgery biopsy.

Diagnóstico de neumocistosis a través de la inmunofluorescencia directa y la PCR anidada en pacientes con enfermedad pulmonar obstructiva crónica / Diagnosis through pneumocystosis direct immunofluorescence and nested PCR in patients with chronic obstructive pulmonary disease

La asociación EPOC- neumocitosis está descrita y existe la necesidad de optimizar la diferenciación entre enfermedad y colonización. Demostrar la presencia del Pneumocistys Jirovecci, como patógeno y/o colonizador. Estudio descriptivo, analítico, de cohorte de pacientes con diagnóstico de EPOC del Hospital General del Oeste (Caracas, Venezuela) durante el periodo de abril – julio 2012 con seguimiento hasta julio de 2013 y aplicación de la técnica de inmunofluorescencia directa (IFD) y/o PCR anidada (PCRa) en muestra de esputo (espontáneo – inducido) durante los periodos asintomáticos o durante la exacerbación del EPOC en seguimiento de un año. Se incluyeron 20 pacientes en el reclutamiento, con seguimiento al primer control de 5 pacientes; de estos solo 2 cumplieron la medición de esputo. Para la tercera evaluación una paciente había fallecido y la otra no cumplió con el seguimiento. Se demostró IFI+ en 10% de los reclutados, todos con clínica de exacerbación de la EPOC. La PCRa se demostró en 45%, 2 con exacerbación y el resto sin exacerbación. De los dos pacientes de seguimiento, una fue positiva para PCRa y no tenía exacerbación, la otra negativa por ambos métodos. Se demostró infección por Pj en los pacientes con EPOC exacerbado a través de IFI y la PCRa señala su positividad en infección pero también en aquellos sin infección o exacerbación documentando así la colonización y potencial fuente de infección para neumocistosis. Se demostró infección por Pj en paciente con exacerbación y colonización a través de la evidencia del genoma del hongo en pacientes sin exacerbación.

Pneumocistosis and COPD association is described and there is a need to differenciate between disease and colonization. To document the presence of Pnemocistys jirovecci as pathogenic or colonizer by direct immunofluoresencence technique (DIF) and/or nested polymerase chain reaction (nPCR) in sputum (spontaneous-induced) during asymptomatic periods or exacerbation of COPD during a year of follow-up. This is a a descriptive, analytic cohort of patients with COPD of the Hospital General del Oeste (Caracas, Venezuela) . They were studied during April - July 2012, with follow-up until July 2013. 20 patients were included. The first control follow up was in 5 patients with only two measures of IFI - PCRa. For the third evaluation one patient had died and the other did not comply with control. IFI + was demonstrated in 10 % of the recruits, all had COPD, exacerbation. PCRa + was demonstrated in 45%, 2 with exacerbation and all other without exacerbation. From the two followed patients one was positive for PCRn and had no exacerbation, the other was negative by both methods. Pj infection was demonstrated in patients with exacerbated COPD by IFI+ and the PCRa positivity in infection but also in those without infection or exacerbation documenting the colonization and potential source of infection for Pj. Pj infection wasdiagnosed in patients with exacerbation COPD and colonization through the evidence of the genome of the fungus in patients without exacerbation.

Evaluación de la microscopía en fresco en el diagnóstico de neumocistosis pulmonar / Microscopio examination in fresh mount preparation for the diagnosis of pulmonary pneumocystosis / Avaliagáo da microscopia a fresco no diagnóstico de pneumocistose pulmonar

Para evaluar la utilidad de la microscopia en fresco en el diagnóstico de la neumocistosis pulmonar (PCP), se aplicó una técnica de inmunofluorescencia directa (IFD) con anticuerpos monoclonales a 50 secreciones respiratorias obtenidas por lavado broncoalveolar y procesadas en forma consecutiva en el Laboratorio de Parasitología, entre el 19 de enero y el 25 de febrero de 2011. Las mismas pertenecían a pacientes con SIDA y diagnóstico presuntivo de PCP, y en todas ellas la investigación de la presencia de exudados espumosos por microscopia en fresco fue negativa. Ninguna de las muestras procesadas resultó positiva para Pneumocystis jiroveci con la IFD. En base a los resultados obtenidos se concluyó que la microscopia en fresco permanece como un método rápido, económico, sencillo y seguro para el diagnóstico de la PCP en los pacientes con SIDA internados en diferentes Salas del Hospital Muñiz. Al igual que en un estudio previo, reveló poseer una sensibilidad similar a la IFD en los pacientes evaluados.

To evaluate the usefulness of fresh microscopy for the diagnosis of pulmonary pneumocystosis (PCP), direct immunofluorescence (DIF) with monoclonal antibodies technique was applied to 50 respiratory secretions obtained by bronchoalveolar lavage and consecutively processed in the Laboratory of Parasitology from January 19, 2011 to February 25, 2011. The samples belonged to AIDS patients with presumptive diagnosis of PCP, and all of them were negative for the search of foamy exudates by wet mountmicroscopy. No positive results were obtained for Pneumocystis jiroveci with the DIF. According to the results obtained, it was concluded that fresh microscopy remains being a rapid, economic, simple and accurate method for the diagnosis of PCP in AIDS patients assisted in different Wards of the Muñiz Hospital. As in a previous study, performed in a similar cohort of patients, fresh microscopy revealed a sensitivity similar to that of DIF when applied to the diagnosis of PCP.

Para avaliar a utilidade da microscopia a fresco no diagnóstico da pneumocistose pulmonar (PCP), foi aplicada uma técnica de imunofluorescencia direta (IFD) com anticorpos monoclonais em 50 secregóes respiratórias obtidas por lavagem broncoalveolar e processadas de forma consecutiva no Laboratório de Parasitologia, entre os dias 19 de janeiro de 2011 e 25 de fevereiro de 2011. As mesmas pertenciam a pacientes com AIDS e diagnóstico presuntivo de PCP, e em todas elas a pesquisa da presenga de esfregagos espumosos por microscopia a fresco foi negativa. Nenhuma das amostras processadas resultou positiva para Pneumocystis jiroveci com a IFD. Com base nos resultados obtidos foi concluido que a microscopia a fresco permanece como um método rápido, económico, simples e seguro para o diagnóstico da PCP nos pacientes com AIDS internados em diferentes. Salas do Hospital Muñiz. Do mesmo modo que num estudo prévio, revelou possuir uma sensibilidade similar a IFD nos pacientes avaliados.

Métodos diagnósticos tintoriales para pneumocystis jirovecii / Diagnostic methods staining for Pneumocystis jirovecii

Se realizó una búsqueda en base de datos Cabdirect bajo los términos ®Pneumocystis-stain¼ entre los años 1990 a 2010., revisándose 109 trabajos relacionados al diagnóstico y estudio de la neumocistosis. Las metodologías empleadas fueron clasificadas en 6 grupos según su frecuencia: Tinción con Gomori-Grocott; Giemsa; Azul de toluidina; Otras tinciones (pap, blanco de calcofluor, gram, may grunwald giemsa);además de inmunofluorescencia directa y PCR (en cualquiera de sus variantes). Se observó una constante en el empleo de las tinciones histológicas en ambas décadas, mayormente con las tinciones de Gomori-Grocott y Giemsa. Sin embargo y como es de esperar, aumenta en la segunda década la tendencia del diagnóstico a través de técnicas moleculares.

Was performed a database search Cabdirect under the terms "pneumonia-stain" between the years 1990 to 2010, 109 papers being revised, and study related to the diagnosis of pneumocystosis. The methodologies used were classified into six groups according to their frequency: Gomori-Grocott stain, Giemsa, toluidine blue, Other stains (pap, calcofluor white, Gram, May Grunwald Giemsa), in addition to direct immunofluorescence and PCR (in any of their variants). There was a constant in the use of histological stains in both decades, mostly with Gomori Grocott staining and Giemsa. However, as expected, increases in the second decade, the trend of diagnosis using molecular techniques.

Diagnóstico microscópico de neumonía por Pneumocystis jirovecii en muestras de lavado broncoalveolar y lavado orofaríngeo de pacientes inmunocomprometidos con neumoníA / Microscopic diagnosis of Pneumocystis jirovecii pneumonia in bronchoalveolar lavage and oropharyngeal wash samples of immunocompromised patients with pneumonia

Introducción. El diagnóstico de neumonía por Pneumocystis jirovecii se fundamenta en la visualización microscópica del hongo en secreciones respiratorias. Técnicas moleculares recientes también lo han detectado en muestras de orofaringe, pero su utilidad diagnóstica es discutible. En Colombia, hay poca información al respecto. Objetivo. Comparar el rendimiento de dos coloraciones, azul de toluidina O e inmunofluorescencia directa, en muestras de lavado broncoalveolar y lavado orofaríngeo en pacientes inmunocomprometidos con neumonía. Materiales y métodos. Se llevó a cabo un estudio transversal de evaluación de pruebas diagnósticas en 166 pacientes inmunocomprometidos con sospecha de neumonía por P. jirovecii. Por protocolo, las muestras de lavado broncoalveolar y orofaríngeo se citocentrifugaron y se colorearon con azul de toluidina e inmunofluorescencia. Se determinó la proporción de resultados positivos con ambas tinciones en cada una de las muestras, y la concordancia entre ellas. Resultados. Se detectaron 24 casos de neumonía por P. jirovecii en las muestras de lavado broncoalveolar (14,5 %), 21 de los cuales fueron positivos por ambas pruebas, mientras que tres casos se detectaron sólo por inmunofluorescencia. Ninguna de las 166 muestras de lavado orofaríngeo fue positiva por cualquiera de estas técnicas. Al comparar las proporciones de resultados positivos, no se encontraron desacuerdos significativos (p=0,63). La concordancia (coeficiente kappa) entre ellas fue de 0,92 (IC95%: 0,84-1). Conclusiones. Ambas coloraciones son útiles para diagnosticar neumonía por P. jirovecii en muestras de lavado broncoalveolar. Sin embargo, el azul de toluidina no detecta, aproximadamente, el 12 % de los casos positivos por inmunofluorescencia. Las muestras de lavado orofaríngeo no son apropiadas para detectar microscópicamente P. jirovecii.

Introduction. The diagnosis of Pneumocystis jirovecii pneumonia is based on observation of the microorganism using several staining techniques in respiratory samples, especially bronchoalveolar lavage and induced sputum. Recently, the fungus also has been detected in oropharyngeal wash samples, but only using molecular tests. Objective. The diagnostic yield of two microscopic stains, toluidine blue O and direct fluorescent antibody, was compared in bronchoalveolar lavage and oropharyngeal wash samples for the detection of P. jirovecii in immunocompromised patients with pneumonia. Materials and methods. Cross-sectional evaluation diagnostic tests were used in 166 immunossupressed patients with suspected P. jirovecii. By protocol, bronchoscopic bronchoalveolar lavage and oropharyngeal wash samples were prepared by cytocentrifugation, and slides were stained with toluidine blue and fluorescent antibody. The proportion of positive results from each stain and concordance between them were determined. Results. Twenty-four cases (14.5%) of P. jirovecii were detected in bronchoalveolar lavage samples. Of them, 21 were positive by both toluidine blue and fluorescent antibody stains, whereas 3 cases were detected by fluorescent antibody alone. None of the 166 oropharyngeal wash samples were positive by either of these techniques. No significant differences were found between proportions from positive results (p=0.63). Concordance (kappa coefficient) between both stains was 0.92 (95% CI: 0.84-1.00). Conclusions. Both techniques were useful to diagnose P. jirovecii in bronchoalveolar lavage samples. However, toluidine blue stain did not detect 12% of fluorescent antibody positive cases. Oropharyngeal wash samples do not provide sufficient material for the microscopic identification of this fungus.

Diagnóstico de neumocistosis en pacientes oncológicos: por la técnica de inmunofluorescencia directa / Neumocistosis in oncological patients: diagnoses for immunofluorescense direct technique

El paciente con enfermedades oncológicas tiene un alto riesgo para desarrollar infecciones respiratorias, y neumonía por Pneumocystis jirovecii. En Venezuela existen pocos estudios sobre la neumocistosis en pacientes oncológicos. El objetivo de este trabajo fue detectar la presencia de Pneumocystis jirovecii en pacientes oncológicos a través de la técnica de inmunofluorescencia directa. Se recibieron, durante 10 meses, 31 muestras respiratorias (lavado broncoalveolar, esputo espontáneo e inducido, aspirados traqueales), de ellas 8 (25,5 por ciento) resultaron positivas. La distribución por tipo de cáncer fue la siguiente: 18 tumores sólidos y 13 leucemias y linfomas. La positividad entre los grupos estudiados no fue estadísticamente significativa (P>0,05). Los exámenes de laboratorio complementarios, relacionados tampoco fueron estadísticamente significativos (P>0,05). Es necesario incluir este diagnóstico en estudio microbiológico diferencial de infecciones del tracto respiratorio inferior en pacientes con cáncer, estos pacientes cursan con una sintomatología general inespecífica y tendrán una alta posibilidad de desarrollar neumocistosis.

The patient with malignancy disease has a high risk to develop respiratory infections for Pneumocystis jirovecii pneumonia. Investigations about pneumocystosis in oncological patients in Venezuela are scarce. The objective of this work was to detect Pneumocystis jirovecii in oncological patients by the method of direct immunofluorescence technique. Thirty one respiratory specimens (bronchoalveolar lavage, spontaneous and induced sputum, and tracheal aspirates) received in 10 months, 8 specimens of them (25.5) were positive the distribution by malignancy disease was the following: 18 solid tumors, and 13 leukemias, and lymphomas. No statistically significant differences were found between the studied groups and positive results (P>0.05). The complementary laboratory tests, related to the presence of Pneumocystis, were not statistically significant either P>0.05). Is necessary to include this diagnosis in the microbiological differential study of low respiratory tract infections in oncological patients, since these patients show unspecific symptoms, and have a high possibility to develop pneumocystosis.

Use of different primer directed sequence amplification by polymerase chain reaction for identification of Pneumocystis jirovecii in clinical samples.

BACKGROUND: Pneumocystis carinii pneumonia (PCP), caused by opportunistic agent Pneumocystis jirovecii (formerly, Pneumocystis carinii is one of the most serious respiratory infection in immunocompromised patients. AIM: The present study was conducted to compare polymerase chain reaction (PCR) assays targetting three different genes of Pneumocystis to study their application in its diagnosis. METHODS: One hundred and eighty (n = 180) clinical samples from 145 immunocompromised patients with clinical suspicion of PCP and 35 samples from control group of 30 immunocompetent individuals with respiratory infections other than PCP were prospectively examined for the presence of Pneumocystis jirovecii (P. jirovecii). All the samples were subjected to microscopic examination, one single [major surface glycoprotein, (MSG)] and two nested [mitochondrial large subunit ribosomal ribonucelic acid, (mtLSU rRNA) and internal transcribed spacer (ITS) region], polymerase chain reaction assays. RESULTS: Microscopic examination was positive in only six (n = 6) patients, whereas single round MSG PCR detected P. jirovecii deoxyribonucleic acid (DNA) in 16 cases. When the clinical samples were tested by mtLSU rRNA and ITS nested PCR assays, it was possible to detect seven additional cases of PCP, making it to a total of 23 cases. None of the clinical specimens in control group (n = 30) were positive by any of the above-mentioned techniques. Amongst the 81 bronchoalveolar lavage (BAL) samples tested, 16 were positive by MSG PCR, while 20 were positive by both nested, i.e., mtLSU rRNA and ITS PCR assays. Similarly, out of 50 sputum samples, only three were positive by MSG, seven by mtLSU rRNA and six by ITS nested PCR assays. CONCLUSION: It has been observed that MSG is relatively more sensitive when single round PCR assay is used for detection of human Pneumocystosis compared to the first (single) rounds of either ITS or mtLSU rRNA nested PCRs. However, the two nested PCRs using ITS and mtLSU rRNA have been found to be more sensitive. On comparison of two nested PCR assays, the results have been more or less comparable.

Ventilação mecânica não-invasiva em paciente com provável pneumonia por pneumocystis jirovecii: relato de caso / Noninvasive mechanical ventilation in patient with pneumocystis jirovecii pneumonia: case report

JUSTIFICATIVA E OBJETIVOS: A pneumonia por Pneumocystis jirovecii tem sido uma das doenças mais comuns e uma complicação infecciosa fatal em pacientes com síndrome da imunodeficiência adquirida. O objetivo deste estudo foi apresentar uma paciente com provável diagnóstico de pneumonia por Pneumocystis jirovecii que recebeu ventilação não-invasiva com pressão positiva. RELATO DO CASO: Paciente do sexo feminino, 25 anos, com diagnóstico provável de pneumonia por Pneumocystis jirovecii grave, recebeu ventilação mecânica não-invasiva com pressão positiva. CONCLUSÕES: Todos os parâmetros melhoraram progressivamente nos primeiros cinco dias. Os resultados sugeriram a eficácia desta medida para otimizar a oxigenação, reverter a hipoxemia e prevenir a intubação traqueal.

BACKGROUND AND OBJECTIVES: Pneumocystis jirovecii pneumonia has been one of the most common diseases and life-threatening infectious complications in acquired immunodeficiency syndrome patients. The objective of the case report was to present a patient with probable diagnosis of Pneumocystis jirovecii pneumonia who received noninvasive positive pressure ventilation. CASE REPORT: A female patient, 25 years old, with probable diagnosis of Pneumocystis jirovecii pneumonia received noninvasive positive pressure ventilation. CONCLUSIONS: All respiratory parameters progressively improved in the first five days. Results suggest the efficacy of this support to improve oxygenation, to revert hypoxemia and to prevent orotracheal intubation.

Induced sputum versus bronchoalveolar lavage in the diagnosis of pneumocystis jiroveci pneumonia in human immunodeficiency virus-positive patients

Induced sputum is a useful technique for assessing airway inflammation, but its role in the diagnosis of lung disease in immunosuppressed patients needs further investigation. This study compared the use of induced sputum and BAL in the diagnosis of pneumocystosis, in HIV patients. From January 1, 2001, to December 30, 2002, HIV-positive patients older than 14 were evaluated at a hospital in Florianópolis, Santa Catarina, Brazil. Patients with respiratory symptoms for seven days or longer, with a normal or abnormal chest X-ray, and those without respiratory symptoms but with an abnormal chest X-ray, were included in the study. All patients were submitted to clinical, radiological and laboratory evaluation, after which induced sputum and bronchoscopy with bronchoalveolar lavage were carried out. The samples were subjected to the following techniques: Gram and Ziehl-Neelsen staining, quantitative culture growth for pyogenic bacteria, direct staining for fungi, culture growth for mycobacteria and fungi, and Grocott-Gomori staining for Pneumocystis jiroveci, as well as total and differential cell counts. The samples with P. jiroveci were selected, as well as the samples for which no etiologic agents were observed. Forty-five patients with a mean age of 34.6, 38 male and 40 Caucasian, comprised the subjects. Interstitial infiltrate was the most frequent radiological pattern (53.3 percent). The induced sputum sensitivity was 58.8 percent, specificity 81.8 percent, predictive positive value 90.9 percent, predictive negative value 39.1 percent and accuracy 64.4 percent, for the diagnosis of pneumocystosis, compared with BAL. Based on these data, induced sputum is a useful technique for the diagnosis of pneumocystosis in HIV patients.

Presentación inhabitual de un caso de neumonía bulosa aguda bilateral por Pneumocystis jiroveci complicada con neumotórax / Unusual presentation of bilateral bullous Pneumocystis jiroveci pneumonia complicated with pneumothorax

En los pacientes con infección por el virus de la inmunodeficiencia humana (VIH), el neumotórax se observa generalmente en etapas avanzadas de la enfermedad, asociado a patógenos como Mycobacterium tuberculosis o Pneumocystis jiroveci, en individuos tabáquicos y drogadictos endovenosos. Presentamos un caso de presentación inhabitual: varón homosexual, 30 años de edad, con tos durante un mes, dificultad respiratoria progresiva y baja de peso, agregándose posteriormente diarrea. Fue hospitalizado con los diagnósticos de insuficiencia respiratoria, neumopatía atípica y observación de infección por VIH. Evolucionó mal, complicándose a los 15 días con neumotórax y bulas pulmonares. El LDH elevado y después la inmunofluorescencia directa (+) confirmaron la etiología: P. jiroveci. El test de ELISA confirmó la pre-existencia de una infección por VIH. A pesar de una terapia enérgica con cotrimoxazol, corticoesteroides y oxígeno, el paciente falleció a los 21 días de su ingreso. Se describen las estrategias recomendadas para el manejo del neumotórax que acontece durante la neumonía por P. jiroveci en los pacientes portadores de infección por VIH.

In patients with human immunodeficiency virus infection, pneumothorax overcomes in advanced stages of the illness, associated with infections by Mycobacterium tuberculosis or Pneumocystis jiroveci, in smokers and intravenous drug users. We present a case with this unusual complication: homosexual man, 30 years of age, with a history of one month of cough, progressive dyspnea, weight loss and diarrhea. He was hospitalized with the diagnosis of atypical pneumonia, respiratory failure and a presumptive HIV infection. His clinical course was complicated by the presence of bullae and pneumothorax by day 15 of hospitalization. The existence of Pneumocystis jiroveci in sputum was confirmed by a direct immunofluorescence test. The patient was treated with sulpha-trimethoprim, steroids, oxygen, but he died 21 days after admittance. The strategies recommended for treatment of pneumothorax appeared during P. jiroveci pneumonia in HIV positive patients are summarized.